Setrusumab vs Placebo for Osteogenesis Imperfecta

Clinical trial NCT05125809 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05125809
Sponsor: Ultragenyx Pharmaceutical Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Osteogenesis Imperfecta

Start date: 2022-02-21
Primary completion: 2025-10-20
Enrollment: 183

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.